DK3291818T3 - Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler i colon - Google Patents
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler i colon Download PDFInfo
- Publication number
- DK3291818T3 DK3291818T3 DK16789978T DK16789978T DK3291818T3 DK 3291818 T3 DK3291818 T3 DK 3291818T3 DK 16789978 T DK16789978 T DK 16789978T DK 16789978 T DK16789978 T DK 16789978T DK 3291818 T3 DK3291818 T3 DK 3291818T3
- Authority
- DK
- Denmark
- Prior art keywords
- colon
- compositions
- methods
- therapeutic agents
- delivering therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156682P | 2015-05-04 | 2015-05-04 | |
| PCT/US2016/030682 WO2016179227A1 (en) | 2015-05-04 | 2016-05-04 | Compositions and methods for delivering therapeutic agents into the colon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3291818T3 true DK3291818T3 (da) | 2019-12-09 |
Family
ID=57218315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16789978T DK3291818T3 (da) | 2015-05-04 | 2016-05-04 | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler i colon |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180140619A1 (da) |
| EP (2) | EP3291818B1 (da) |
| JP (1) | JP6814162B2 (da) |
| KR (1) | KR20170142181A (da) |
| AU (2) | AU2016257911B2 (da) |
| CA (1) | CA2984111A1 (da) |
| DK (1) | DK3291818T3 (da) |
| ES (1) | ES2761636T3 (da) |
| WO (1) | WO2016179227A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10493107B2 (en) * | 2014-06-09 | 2019-12-03 | Cornell University | Implantable therapeutic delivery system and methods thereof |
| EP3291818B1 (en) * | 2015-05-04 | 2019-10-30 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for delivering therapeutic agents into the colon |
| WO2020084530A1 (en) * | 2018-10-24 | 2020-04-30 | Ferring B.V. | Mucoadhesive pharmaceutical compositions of corticosteroids |
| US20210361602A1 (en) * | 2020-05-22 | 2021-11-25 | Intact Therapeutics, Inc. | Dosing methods for treating inflammatory bowel conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4350690A (en) * | 1980-10-27 | 1982-09-21 | Cressington Investments Ltd. | Steroid composition |
| FR2586587B1 (fr) * | 1985-08-30 | 1987-10-23 | Adir | Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| KR20090034385A (ko) * | 2006-07-19 | 2009-04-07 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 염증성 장질환을 치료하기 위한 5-아미노살리실산 함유 약제 및 인지질의 제제 |
| AU2009333303A1 (en) * | 2008-12-17 | 2011-08-11 | Altheus Therapeutics, Inc. | Enema formulations |
| EP3291818B1 (en) * | 2015-05-04 | 2019-10-30 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for delivering therapeutic agents into the colon |
-
2016
- 2016-05-04 EP EP16789978.0A patent/EP3291818B1/en active Active
- 2016-05-04 EP EP19206063.0A patent/EP3659607A1/en active Pending
- 2016-05-04 US US15/571,644 patent/US20180140619A1/en not_active Abandoned
- 2016-05-04 AU AU2016257911A patent/AU2016257911B2/en active Active
- 2016-05-04 CA CA2984111A patent/CA2984111A1/en not_active Abandoned
- 2016-05-04 ES ES16789978T patent/ES2761636T3/es active Active
- 2016-05-04 KR KR1020177033487A patent/KR20170142181A/ko not_active Application Discontinuation
- 2016-05-04 DK DK16789978T patent/DK3291818T3/da active
- 2016-05-04 JP JP2017558481A patent/JP6814162B2/ja active Active
- 2016-05-04 WO PCT/US2016/030682 patent/WO2016179227A1/en unknown
-
2021
- 2021-05-14 AU AU2021203094A patent/AU2021203094A1/en not_active Abandoned
- 2021-05-27 US US17/332,506 patent/US20210330682A1/en not_active Abandoned
- 2021-05-27 US US17/332,431 patent/US20210283148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021203094A1 (en) | 2021-06-10 |
| JP2018515511A (ja) | 2018-06-14 |
| EP3659607A1 (en) | 2020-06-03 |
| AU2016257911A1 (en) | 2017-11-09 |
| EP3291818A1 (en) | 2018-03-14 |
| ES2761636T3 (es) | 2020-05-20 |
| CA2984111A1 (en) | 2016-11-10 |
| EP3291818A4 (en) | 2018-12-12 |
| JP6814162B2 (ja) | 2021-01-13 |
| US20180140619A1 (en) | 2018-05-24 |
| AU2016257911B2 (en) | 2021-02-18 |
| US20210283148A1 (en) | 2021-09-16 |
| WO2016179227A1 (en) | 2016-11-10 |
| US20210330682A1 (en) | 2021-10-28 |
| EP3291818B1 (en) | 2019-10-30 |
| KR20170142181A (ko) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| DK3350157T3 (da) | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3303317T3 (da) | Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
| DK3234107T3 (da) | B-celler til in vivo-levering af terapeutiske midler | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| HK1252778A1 (zh) | 細胞擴增方法和治療組合物 | |
| DK4119569T3 (da) | Konjugerede antisense-forbindelser til anvendelse i behandling | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3212776T3 (da) | Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| DK3608334T3 (da) | Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf | |
| DK3240821T3 (da) | Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde |